Detalles de la búsqueda
1.
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study.
Haematologica
; 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38356463
2.
Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy.
Eur J Haematol
; 96(4): 417-24, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26190662
3.
Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study.
Br J Haematol
; 190(5): e289-e292, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31792926
4.
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.
Haematologica
; 100(9): 1207-13, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26069291
5.
Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
Biol Blood Marrow Transplant
; 19(1): 69-74, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22897964
6.
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.
Clin Lymphoma Myeloma Leuk
; 21(6): 413-420, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33741302
7.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Haematologica
; 93(4): 560-5, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18322252
8.
The safety of daratumumab for the treatment of multiple myeloma.
Expert Opin Drug Saf
; 16(6): 753-760, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28490215
9.
Infectious complications in patients with newly diagnosed multiple myeloma: A complication from the past?
Leuk Lymphoma
; 57(2): 258-268, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26428053
10.
Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma.
Leuk Lymphoma
; 56(2): 415-9, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24828869
11.
Quality control of bacterial contamination in autologous peripheral blood stem cells for transplantation.
Haematologica
; 89(10): 1232-7, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15477209
12.
Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial.
Leuk Lymphoma
; 50(2): 216-22, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19197734
13.
Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Biol Blood Marrow Transplant
; 13(12): 1448-54, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-18022574
14.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
Blood
; 108(7): 2165-72, 2006 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16772605
Resultados
1 -
14
de 14
1
Próxima >
>>